- 第3日 6月24日（金） 9:40～10:00 A会場（メインホール）
The number of patients with Alzheimer's disease is increasing every year and is expected to continue to grow. This is a major problem in many countries and pressures the health care economy. Objective diagnostic methods for Alzheimer's disease include imaging such as MRI and measurement of amyloid peptides in cerebrospinal fluid, but imaging is available at very limited facilities, and cerebrospinal fluid sampling is highly invasive and unsuitable for repeated diagnosis. However, about two years ago, the method of diagnosing Alzheimer's disease changed dramatically. Plasma p-tau217 and even p-tau181 began to show promise as plasma biomarkers for Alzheimer's disease. However, there is still no effective treatment for Alzheimer's disease. If the pathogenic mechanism of Alzheimer's disease is clarified, treatment options may increase. Since Alzheimer's disease does not develop spontaneously in experimental animals, we now have only existing hypothetical models. In other words, current animal models are inadequate for creating new hypotheses. Therefore, human samples, especially blood samples, which are relatively easy to obtain, are used widely. However, blood is isolated from the site of the lesion, and any material leaking from a particular site will be diluted by the large volume of blood. Under these difficult situations, we are challenging to construct a hypothesis using multi-omics with mass spectrometry and an immunoassay panel. On the day of the meeting, I plan to present the progress and challenges in the project.